E-LIB Suche - Ergebnisse für: Hwa, Yi

1

Outcomes of patients with multiple myeloma refractory to st..:

Goel, Utkarsh ; Charalampous, Charalampos ; Kapoor, Prashant...
Blood Cancer Journal. 14 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

2

P812: PREDICTING HIGH-RISK DISEASE BIOLOGY USING ARTIFICIAL..:

Shreve, Jacob ; Charalampous, Charalampos ; Kourelis, Taxiarchis...
HemaSphere. 7 (2023) S3 - p. e0586106 , 2023

Link: https://doi.org/10.1097/..

3

Defining drug/drug class refractoriness vs lines of therapy..:

Goel, Utkarsh ; Charalampous, Charalampos ; Kapoor, Prashant...
Blood Cancer Journal. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

4

P-281 Comparison of daratumumab-based regimens as second-li..:

Charalampous, Charalampos ; Goel, Utkarsh ; Kapoor, Prashant...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S191 , 2023

Link: https://doi.org/10.1016/..

5

P-262 Retreatment with previously refractory drugs in multi..:

Goel, Utkarsh ; Charalampous, Charalampos ; Kapoor, Prashant...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S180 , 2023

Link: https://doi.org/10.1016/..

6

P885: SOLITARY PLASMACYTOMA: SINGLE INSTITUTION EXPERIENCE ..:

Charalampous, Charalampos ; Claveau, Jean-Sebastien ; Kapoor, Prashant...
HemaSphere. 7 (2023) S3 - p. e81981ce , 2023

Link: https://doi.org/10.1097/..

7

P-261 Comparison of different cutoffs of time from last dru..:

Goel, Utkarsh ; Charalampous, Charalampos ; Kapoor, Prashant...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S179-S180 , 2023

Link: https://doi.org/10.1016/..

8

Comparison of daratumumab-based regimens as second-line the..:

Charalampous, Charalampos ; Goel, Utkarsh ; Kapoor, Prashant...
Blood Cancer Journal. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

9

P-093 Solitary plasmacytoma: single institution experience ..:

Charalampous, Charalampos ; Claveau, Jean-Sebastien ; Kapoor, Prashant...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S85-S86 , 2023

Link: https://doi.org/10.1016/..

10

Thrombosis in multiple myeloma: Risk estimation by inductio..:

Charalampous, Charalampos ; Goel, Utkarsh ; Kapoor, Prashant...
American Journal of Hematology. 98 (2023) 3 - p. 413-420 , 2023

Link: https://doi.org/10.1002/..

11

Outcomes of patients with primary refractory multiple myelo..:

Charalampous, Charalampos ; Goel, Utkarsh ; Kapoor, Prashant...
Blood Advances. 7 (2023) 16 - p. 4371-4380 , 2023

Link: https://doi.org/10.1182/..

12

P-126 Adding value of serum-free light chain in assessing r..:

Askari, Elham ; Rajkumar, Vincent ; Murray, David...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S104-S105 , 2023

Link: https://doi.org/10.1016/..

13

Muscle and fat composition in patients with newly diagnosed..:

Abdallah, Nadine H. ; Nagayama, Hiroki ; Takahashi, Naoki...
Blood Cancer Journal. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

14

Natural history, predictors of development of extramedullar..:

Zanwar, Saurabh ; Ho, Matthew ; Lin, Yi...
American Journal of Hematology. 98 (2023) 10 - p. 1540-1549 , 2023

Link: https://doi.org/10.1002/..

15

P-003 Clinical outcomes among multiple myeloma and lymphoma..:

Balandan, Kristina ; Hwa, Yi ; Bansal, Radhika...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S34 , 2023

Link: https://doi.org/10.1016/..